QUERY LOG / TESAMORELIN
Questions About Tesamorelin
Direct answers drawn from the published record, each one cited where it makes a quantitative claim.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44), stabilized by an N-terminal trans-3-hexenoic-acid group [7]. It is FDA-approved (2010) only to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy [5]; every other use is off-label.
What does tesamorelin do?
In the pivotal 26-week Phase 3 RCT (n=412), tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% versus a 5.0% increase on placebo, lowered triglycerides, and raised IGF-1 by 81% [1]. It stimulates the body's own pulsatile growth hormone rather than supplying exogenous GH [4].
How does tesamorelin work?
It binds the GHRH receptor on pituitary somatotrophs, activating the Gs/cAMP/PKA cascade to stimulate pulsatile endogenous growth hormone [4]. That GH drives hepatic IGF-1 synthesis (in healthy men, +181 ug/L) [4], and GH and IGF-1 together promote lipolysis preferentially in visceral fat.
Is tesamorelin a growth hormone?
No. Tesamorelin is not growth hormone; it is a GHRH analogue that prompts the pituitary to release the body's own GH in a pulsatile (episodic) pattern, as confirmed by PK-PD modeling [10]. It amplifies the natural GH rhythm rather than supplying exogenous hormone.
Is tesamorelin a GLP-1?
No. Tesamorelin is a GHRH receptor agonist that stimulates pulsatile endogenous growth hormone [4]; it is mechanistically unrelated to the GLP-1 receptor agonist class. It acts on pituitary somatotrophs, not on incretin pathways.
Is tesamorelin FDA approved?
Yes, but narrowly: tesamorelin was FDA-approved in 2010 (NDA 022505) solely to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. There is no FDA indication outside HIV-associated lipodystrophy; every other use is off-label.
Will tesamorelin help me lose belly fat?
In HIV-associated lipodystrophy, tesamorelin 2 mg/day selectively reduced visceral abdominal fat (-15.2% at 26 weeks) [1], and a 2026 meta-analysis of five RCTs confirmed a pooled visceral-fat reduction of -27.71 cm2 [14]. Efficacy outside the HIV-lipodystrophy population has not been established by large RCTs.
Does tesamorelin burn belly fat?
In the studied HIV-lipodystrophy population, tesamorelin selectively reduced visceral (intra-abdominal) fat while generally sparing subcutaneous fat and BMI; the 2014 JAMA RCT reported a -42 cm2 visceral-fat treatment effect [3]. These are research outcomes, not a fat-loss promise for other populations.
How long does it take to see fat loss from tesamorelin?
Pivotal trials measured significant visceral-fat reduction at 26 weeks [1], with the effect sustained to 52 weeks (-18%) [2]. These are trial timepoints in HIV patients, not a recommendation or a general-population expectation, and the fat reaccumulates when dosing stops.
Does tesamorelin work for fat loss in non-HIV users?
Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy. Non-HIV human data are limited to a mechanistic study in healthy men [4]; generalizability to non-HIV fat loss is mechanistically plausible but not established by large RCTs, and all such use is off-label.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In a 6-month JAMA RCT of antiretroviral-treated HIV adults, tesamorelin reduced hepatic lipid by a net -2.9% [3]; a 2026 meta-analysis reported a pooled hepatic-fat reduction of -4.28% [14]. NAFLD use in HIV is investigational and not an FDA-approved indication.
How does tesamorelin affect the liver in NAFLD?
By stimulating GH/IGF-1 and reducing visceral fat, tesamorelin lowered hepatic fat fraction in HIV patients (net -2.9% hepatic lipid) [3]. It is rated unlikely to cause clinically apparent liver injury (NIH LiverTox likelihood score E), with no attributable liver-injury cases reported in trials [5].
Can tesamorelin reduce liver fat?
In HIV-associated fatty liver, tesamorelin 2 mg/day reduced hepatic lipid versus placebo (net -2.9%; Stanley 2014 JAMA) [3], and the 2026 five-RCT meta-analysis found a pooled hepatic-fat-fraction reduction of -4.28% (P<0.001) [14]. These are research endpoints in HIV cohorts.
How does tesamorelin differ from sermorelin?
Tesamorelin is a stabilized full-length GHRH(1-44) analogue carrying an N-terminal trans-3-hexenoic-acid group that resists DPP-IV cleavage; sermorelin is the truncated GHRH(1-29) [7]. A clinical review summarizes this structural distinction and the Phase 3 evidence behind tesamorelin's visceral-fat reduction in HIV lipodystrophy [7].
Is tesamorelin better than sermorelin?
The published evidence bases differ sharply: tesamorelin has two pivotal Phase 3 RCTs and a 2026 meta-analysis in HIV-associated lipodystrophy [1][14], whereas sermorelin lacks comparable visceral-fat RCTs. The literature does not establish a head-to-head superiority claim, and no direct comparative trial has been reported.
Can you stack or take tesamorelin and sermorelin together?
No peer-reviewed co-administration trial of tesamorelin with sermorelin (or with ipamorelin or CJC-1295) has been published; the pivotal RCTs studied tesamorelin as monotherapy [1]. Secretagogue-physiology studies show GHRH and GH-releasing peptides act through distinct pathways [8], but any combination remains uncharacterized in the clinical literature.
What is the half-life of tesamorelin?
Population PK modeling reported apparent plasma clearance of ~1,060 L/h with no clinically relevant demographic covariates [6]; secondary sources describe a terminal half-life on the order of ~26-38 minutes. Despite rapid clearance, IGF-1 elevation persists across the dosing interval [4].
How long does tesamorelin stay in your system?
Plasma exposure is short, with rapid clearance (~1,060 L/h apparent clearance) and the absorbed fraction ~13% higher by day 14 than day 1 [6]. The downstream GH/IGF-1 response outlasts the parent peptide, which is why a once-daily subcutaneous regimen was studied [4].
What are the side effects of tesamorelin?
Trials reported injection-site reactions and GH-class effects, with serum IGF-1 rising as expected for GH-axis stimulation [4]. The 52-week program found glucose changes not clinically significant [2], and LiverTox rates tesamorelin unlikely to cause clinically apparent liver injury (score E) [5].
Does tesamorelin cause water retention?
Fluid retention is a recognized growth-hormone-class effect; because tesamorelin stimulates endogenous GH and raises IGF-1, GH-axis effects are expected [4]. The pivotal 52-week program characterized the overall adverse-event profile without serious events attributed to the drug [2].
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men, tesamorelin did not significantly affect fasting glucose or insulin-stimulated glucose uptake [4], and 52-week glucose changes in HIV patients were not clinically significant [2]. Modest glucose perturbation can accompany GH-axis stimulation, so monitoring is warranted in prediabetes or dysglycemia, though a dedicated type-2-diabetes trial found no significant HbA1c change.
Who should not take tesamorelin / who should avoid it?
Because tesamorelin stimulates the GH/IGF-1 axis, active malignancy is treated as a key caution in the literature, and individuals with dysglycemia warrant glucose monitoring [5]. Tesamorelin is also prohibited in sport under WADA category S2 [15]. Research-grade material is supplied for laboratory use and is not for human self-administration.